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f Cancer Therapy
e read with great interest the state-of-the-art paper by Yeh and
ickford (1) on the cardiovascular complications of cancer therapy.
lthough the review on monitoring for chemotherapy associated
eft ventricular (LV) dysfunction discussed the role of established
oninvasive tools, such as radionuclide ventriculography and echo-
ardiography, evidence on emerging tools such as cardiac magnetic
esonance (CMR) was not provided. The potential influence of
ancer therapy on the vascular system was also not addressed.
CMR, with its heightened spatial resolution compared with
hese established modalities, has become a valuable tool in the
ssessment of myocardial function, perfusion, and tissue charac-
erization (2). In addition, CMR has low intra- and interobserver
ariability and high test-retest reproducibility for measurement of
V function (3,4), characteristics that are crucial in clinical
ituations requiring accurate serial monitoring of LV function that
ccurs in cancer patients receiving potentially cardiotoxic therapy
or cancer. Also, CMR is considered by the American College of
ardiology Foundation and multiple professional societies as an
ppropriate tool for evaluation of LV function in patients with
echnically suboptimal echocardiograms and evaluation of specific
ardiotoxic therapy associated with cardiomyopathy (5).
Tissue characterization by CMR is a robust technique of
rognostic importance (6). In a pilot study, Wassmuth et al. (7)
emonstrated the strength of CMR to detect subclinical cardio-
oxic effects of anthracyclines. Increase of relative myocardial
ontrast enhancement of 5 on day 3 compared with baseline
redicted a significant decline in LV ejection fraction at 28 days
p  0.05).
An emerging concern for cancer survivors is the increasing
revalence of cardiovascular events (8). For survivors of breast
ancer and hematologic malignancies, cardiovascular events are the
econd most common cause of mortality after cancer recurrence
8). At present, there are few studies that have been performed to
dentify subclinical markers of increased cardiovascular events in
ancer survivors. Increased aortic stiffness is an independentredictor of cardiovascular events beyond the Framingham score
9,10). In a soon-to-be published prospective case-control study,
haosuwannakit et al. (11), observed a significant increase in
MR measures of aortic stiffness among cancer patients within 4
onths of exposure to anthracycline chemotherapy. As cancer
urvivors experience higher incidence of cardiovascular events,
urther studies will be necessary to identify subclinical markers of
ardiovascular disease.
CMR holds great potential in the comprehensive cardiovascular
valuation of cancer patients on therapy and should therefore be
ncluded in discussions on contemporary cardiovascular imaging of
his growing patient population.
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e thank Drs. Ntim and Hundley for their interest in our paper
1) and their comments regarding the role of cardiac magnetic
esonance (CMR) in the evaluation of cardiac complications of
ancer therapy. We agree that CMR has a well-defined and
xpanding role in the evaluation and management of cardiac
isease in general, with specific value in cardiovascular structure,
unction, and physiology (2). The use of CMR in cardiotoxicity,
owever, has only been evaluated in a preliminary fashion. One
tudy (3) with a limited number of patients and without biopsy
orrelation, suggested that CMR could be used as a prognosticator
f future cardiomyopathy. A 10-patient case series evaluated the
alue of CMR in confirming the presence of left ventricular
ysfunction and demonstrated late gadolinium enhancement in
atients with cardiomyopathy. Delayed enhancement CMR was
lso used to demonstrate abnormalities in patients with late-onset
ardiomyopathy in isolated case reports (4,5).
The ability of delayed gadolinium enhancement CMR to
iagnose myocardial pathology makes it an attractive method to
valuate patients at risk for antineoplastic cardiotoxicity. However,
s of yet there have been no studies correlating findings of CMR
o endomyocardial biopsies, which is the gold standard. In addi-
ion, the total number of patients studied to this day remains very
mall. Because of this lack of data we do not routinely use CMR
t M. D. Anderson Cancer Center for the purpose of screening or
ollowing patients with cardiotoxicity.
In conclusion, whereas we felt it would be premature to include
MR in a state-of-the-art paper, we feel strongly that this
echnology merits further investigation and certainly has the
otential to benefit patients with cardiotoxicity related to cancer
reatment.Edward T. H. Yeh, MD
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